Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MRG-110 Following Intradermal Injection in Healthy Volunteers

MRG‐110 is intended to promote the growth of new blood vessels by inhibiting a molecule called miR‐92a. MRG‐110 is being studied to determine if it can accelerate healing of wounds by improving blood flow into the wound area. The primary objective of this study is to investigate the safety and tolerability of MRG‐110 when injected into the skin at the site of a small skin wound in normal healthy volunteers. Another objective is to study the pharmacokinetics of MRG‐110 (the movement of a drug into, through and out of the body). Participants in the clinical trial will receive either a single dose or multiple doses of MRG‐110 and/or placebo. Blood samples, urine samples and skin biopsies will be collected to measure how MRG‐110 is processed by the body, and how the body responds when exposed to MRG‐110.